Skip to main content

Cancer Immunotherapy Market to Reach USD 251.41 Billion By 2032 | Emergen Research

Demand for cancer immunotherapy is projected to increase in the coming years owing to rising awareness of the numerous cancer treatment alternatives.

Vancouver, Dec. 11, 2023 (GLOBE NEWSWIRE) — The global Cancer Immunotherapy Market size was USD 84.53 Billion in 2021 and is expected to register a revenue CAGR of 10.4% during the forecast period, according to latest analysis by Emergen Research. The demand for cancer immunotherapy is anticipated to rise in the upcoming years as more people become aware of the various cancer treatment options. The primary driver for the cancer immunotherapy market is the anticipated increase in cancer incidence.

The demand for cancer immunotherapy is anticipated to rise in the upcoming years as more people become aware of the various cancer treatment options. The primary driver for the cancer immunotherapy market is the anticipated increase in cancer incidence. The World Health Organization (WHO) estimates that around 10 million deaths, or almost one in six deaths, would be attributable to cancer in 2020, making it the leading cause of death worldwide. The most common forms of cancer include breast, lung, colon, rectum, and prostate. Additionally, the development of various cell therapies is being funded by government agencies and cancer research facilities, which is boosting market revenue.

Download FREE Sample PDF here @ https://www.emergenresearch.com/request-sample/63

Another significant element fueling the expansion of market revenue is the development of bioinformatics tools to enhance drug development. Biopharmaceutical businesses usually struggle with the choice of protein molecules and drug design, when developing new medications. The use of bioinformatics tools is one of the most significant and successful methods for developing clinical medicine for clinical research & applications and improving outcomes for cancer patients. These techniques also aid in determining the roles that proteins play after mutations, increasing the possibility that the medication will be made successfully. Due to the rising interest in this technique among pharmaceutical, biotechnology, and research institutes to increase the number of cancer immunotherapy research projects, the market for cancer immunotherapy is attracting greater investment.

Scope of Research

Report DetailsOutcome
Market size in 2021USD 84.53 Billion
CAGR (2023–2032)10.4%
Revenue forecast to 2032USD 251.41 Billion
Base year for estimation2022
Historical data2019–2021
Forecast period2023–2032
Quantitative unitsRevenue in USD Billion and CAGR in % from 2023 to 2032
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments coveredTechnology, application, end-use, and region
Regional scopeNorth America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country scopeU.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Benelux, Rest of Europe, China, India, Japan, South Korea, Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, Rest of MEA
Key companies profiledAmgen Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Seagen Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Gilead Sciences, Inc., Bayer AG, and Sanofi
Customization scope10 hours of free customization and expert consultation

Emergen Research is Offering Limited Time Discount (Grab a Copy at Discounted Price Now) @ https://www.emergenresearch.com/request-discount/63

Major Companies and Competitive Landscape

The global cancer immunotherapy market is fairly fragmented, with many large and medium-sized players accounting for the majority of market revenue. Major players are deploying various strategies, entering into mergers & acquisitions, strategic agreements & contracts, developing, and introducing more effective therapies. Some major players included in the global cancer immunotherapy market report are:

  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Seagen Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • Bayer AG
  • Sanofi

Strategic Development

  • On 28 February 2022, the U.S. Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with Relapsed or Refractory Multiple Myeloma (RRMM) two single domain antibodies that target the B-Cell Maturation Antigen (BCMA), after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
  • On 29 July 2020, Beacon Medicare Limited (BML), based in Bangladesh introduced a new drug under the generic name Pembrolizumab, marketed under the brand name ‘Pembroxim,’ in injection form, to aid patients battling the spread of specific cancer kinds around the globe. The drug will be used in immunotherapy for cancers of the stomach, head, and neck, melanoma, and Hodgkin lymphoma. It is advised to inject slowly into the patient’s veins.

Direct Order Can Be Placed Through This Link [Exclusive Copy] @ https://www.emergenresearch.com/select-license/63

Some Key Highlights from the Report

  • The global market for cancer immunotherapy is divided into hospitals, cancer research institutes, and clinics based on end-use. In 2021, the hospital market contributed a sizeable portion of total revenue. This is explained by the rise in patient admissions. Most hospitals place a higher priority on addressing symptoms when it comes to cancer immunotherapy in particular. Modern cancer therapies are provided at these centres that boost patients’ immune systems. This group of pharmaceuticals includes cancer vaccinations, cellular therapies, and other experimental drugs. Hospitals continue to be the preferred medical location because they contain the most advanced technology for precise diagnosis and treatment. The level of medical care offered by hospitals has increased as a result of widespread use of innovative therapies, tests, and equipment, which is financed by both public and commercial sources.
  • The U.S. Food and Drug Administration (FDA) granted approval for CARVYKTI (ciltacabtagene autoleucel; cilta-cel) on February 28, 2022, for the treatment of adults with relapsed or resistant multiple myeloma (RRMM) following four or more prior lines of therapy, including proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody.
  • Pembrolizumab, also known as Pembroxim, is an injection-only new medication that was released on July 29, 2020 by Bangladesh-based Beacon Medicare Limited (BML), to help patients combat the global spread of specific cancer types. The medication will be utilized in immunotherapy for melanoma, Hodgkin lymphoma, stomach, head, and neck malignancies. Injecting is suggested.

Browse the complete Global Cancer Immunotherapy Market Research Report – Industry Analysis, Size, Share, Growth, Trends @ https://www.emergenresearch.com/industry-report/cancer-immunotherapy-market

For the purpose of this report, Emergen Research has segmented the global cancer immunotherapy market based on technology type, end user, application, and region:

  • Technology Type Outlook (Revenue, USD Million; 2019-2032)
    • Monoclonal Antibodies
    • Cytokines & Immunomodulators
    • Others
  • End user Outlook (Revenue, USD Million; 2019-2032)
    • Hospitals
    • Cancer Research Centers
    • Clinics
  • Application Outlook (Revenue, USD Million; 2019-2032)
    • Lung Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Melanoma
    • Prostate Cancer
    • Head & Neck Cancer
    • Others
  • Regional Outlook (Revenue, USD Million; 2019–2032)
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Rest of APAC
    • LAMEA
      • Latin America
      • Middle East
      • Africa

Curated Reports You Shouldn’t Miss: Dive In Now!

Brachytherapy Market By Type, By Application, By End-Users, Forecasts to 2027

Big Data in Healthcare Market By Component (Software, Services), By Deployment (On-Premises, Cloud), By Analytics Type (Predictive Analytics, Descriptive Analytics), By Application (Clinical Analytics, Financial Analytics), By End User (Hospitals and Clinics), and By Region, Forecasts to 2027

Smart Gloves Market Analysis By Usage (Media and Connected Device, Fitness Tracker, Specific Health Monitoring Device, Others), By End-user (Healthcare, Fitness, Industrial, Others), By Region, Forecast to 2027

Bioelectric Medicine Market By Product Type (Cardioverter defibrillators, Spectromolecular, Cohlear implants, Spinal cord stimulators, Brain stimulators, Sacral and vagus nerve stimulators), By Application (Arrhythmia, Pain Management, Sensorineural hearing loss, Parkinson’s disease, Tremor, Depression), By End User (Hospitals, Ambulatory Surgery Centers, Diagnostic Centers) and By Regions Forecasts to 2027

Blockchain in Genomics Market By Service, By Business Model, By Application (Data Storage & Security, Data Sharing and Monetization, Automated Health Insurance), By End-Use (Hospitals, Pharmaceutical and Biotechnology, Research Institutes), By Region Forecasts to 2027

Mammography Workstations Market By Modality (Standalone, Multimodal), By Application (Advance Imaging, Diagnostic Screening, Clinical Review), By End-use (Academia, Hospitals, Breast Care Centers) and By Region, Forecasts to 2027

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: https://www.emergenresearch.com/

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Explore Our Japanese Version: Cancer Immunotherapy Market

Explore Our Blogs and Insights Section: https://www.emergenresearch.com/insights

Read our Press Release @ https://www.emergenresearch.com/press-release/global-cancer-immunotherapy-market

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.